NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018)
By "NextCell" or "Company" is meant NextCell Pharma AB with organization number 556965-8361. Amount in brackets in the report refers to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31.
First half (2017-09-01 till 2018-02-28)
- Net sales amounted to SEK 391 204 (120 594).
- Operating result amounted to SEK -7 524 256 (-4 863 506).
- Cash and bank amounted to SEK 9 444 381 (4 124 396).
- Result per share* amounted to SEK -0,88 (-1,86).
- Solidity** amounted to 82 (69) %.
Second quarter (2017-12-01 till 2018-02-28)
- Net sales amounted to SEK 232 850 (37 908).
- Operating result amounted to SEK -4 313 441 (-2 399 780).
- Result per share* amounted to SEK -0,51 (-0,68).
*Result per share: operating results divided by the average number of shares. Average number of shares for the first half of 2017/2018: 8,505,425 (2,624,260). Average number of shares for the second quarter 2017/2018: 8,505,425 (3,5297,250).
** Equity ratio: shareholders' equity of the balance sheet total.
The full report is attached to this press release and available on the company website www.nextcellpharma.com
För mer information om NextCell Pharma AB, vänligen kontakta:
Mathias Svahn, VD
Leo Groenewegen, CFO
Telefon: 08-735 5595
E-post: info@nextcellpharma.com
www.nextcellpharma.com (http://file//hm.local/sedermera.se/gemensam/Corp/Externa/NextCell Pharma/KOM/Pressmeddelanden/170713 - Första dag för handel/www.nextcellpharma.com)About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmuneand inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.
